Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

64 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The efficacy and safety of direct acting antiviral treatment and clinical significance of drug-drug interactions in elderly patients with chronic hepatitis C virus infection.
Vermehren J, Peiffer KH, Welsch C, Grammatikos G, Welker MW, Weiler N, Zeuzem S, Welzel TM, Sarrazin C. Vermehren J, et al. Among authors: peiffer kh. Aliment Pharmacol Ther. 2016 Oct;44(8):856-65. doi: 10.1111/apt.13769. Epub 2016 Aug 23. Aliment Pharmacol Ther. 2016. PMID: 27549000 Free article.
Impact of HBV genotype and mutations on HBV DNA and qHBsAg levels in patients with HBeAg-negative chronic HBV infection.
Kuhnhenn L, Jiang B, Kubesch A, Vermehren J, Knop V, Susser S, Dietz J, Carra G, Finkelmeier F, Grammatikos G, Zeuzem S, Sarrazin C, Hildt E, Peiffer KH. Kuhnhenn L, et al. Among authors: peiffer kh. Aliment Pharmacol Ther. 2018 Jun;47(11):1523-1535. doi: 10.1111/apt.14636. Epub 2018 Apr 10. Aliment Pharmacol Ther. 2018. PMID: 29637585 Clinical Trial.
Impaired HBsAg release and antiproliferative/antioxidant cell regulation by HBeAg-negative patient isolates reflects an evolutionary process.
Basic M, Thiyagarajah K, Glitscher M, Schollmeier A, Wu Q, Görgülü E, Lembeck P, Sonnenberg J, Dietz J, Finkelmeier F, Praktiknjo M, Trebicka J, Zeuzem S, Sarrazin C, Hildt E, Peiffer KH. Basic M, et al. Among authors: peiffer kh. Liver Int. 2024 Oct;44(10):2773-2792. doi: 10.1111/liv.16048. Epub 2024 Jul 30. Liver Int. 2024. PMID: 39078064
Rare HCV subtypes and retreatment outcomes in a cohort of European DAA-experienced patients.
Dietz J, Graf C, Berg CP, Port K, Deterding K, Buggisch P, Peiffer KH, Vermehren J, Dultz G, Geier A, Reiter FP, Bruns T, Schattenberg JM, Durmashkina E, Gustot T, Moreno C, Trauth J, Discher T, Fischer J, Berg T, Kremer AE, Müllhaupt B, Zeuzem S, Sarrazin C; European HCV Resistance Study Group. Dietz J, et al. Among authors: peiffer kh. JHEP Rep. 2024 Mar 25;6(7):101072. doi: 10.1016/j.jhepr.2024.101072. eCollection 2024 Jul. JHEP Rep. 2024. PMID: 39006503 Free PMC article.
Terlipressin therapy is associated with increased risk of colonisation with multidrug-resistant bacteria in patients with decompensated cirrhosis.
Mücke MM, Hernández-Tejero M, Gu W, Kuhn M, Janz M, Keller MI, Fullam A, Altepeter L, Mücke VT, Finkelmeier F, Schwarzkopf KM, Cremonese C, Hunyady PM, Heilani MW, Uschner FE, Schierwagen R, Brol MJ, Fischer J, Klein S, Peiffer KH, Hogardt M, Shoaie S, Coenraad MJ, Bojunga J, Arroyo V, Zeuzem S, Kempf VAJ, Welsch C, Laleman W, Bork P, Fernandez J, Trebicka J; MICROB-PREDICT and PREDICT Study Group of the EASL-CLIF Consortium. Mücke MM, et al. Among authors: peiffer kh. Aliment Pharmacol Ther. 2024 Apr;59(7):877-888. doi: 10.1111/apt.17899. Epub 2024 Feb 27. Aliment Pharmacol Ther. 2024. PMID: 38414095
Role of endoscopy in hepatology.
Laleman W, Peiffer KH, Tischendorf M, Ullerich HJ, Praktiknjo M, Trebicka J. Laleman W, et al. Among authors: peiffer kh. Dig Liver Dis. 2024 Jul;56(7):1185-1195. doi: 10.1016/j.dld.2023.11.032. Epub 2023 Dec 26. Dig Liver Dis. 2024. PMID: 38151452 Review.
64 results